Compare LCTX & HYLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | HYLN |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.6M | 328.1M |
| IPO Year | 1996 | 2019 |
| Metric | LCTX | HYLN |
|---|---|---|
| Price | $1.32 | $6.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $6.25 | $5.00 |
| AVG Volume (30 Days) | 1.3M | ★ 4.9M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,556,000.00 | $3,475,000.00 |
| Revenue This Year | $109.40 | $197.93 |
| Revenue Next Year | N/A | $301.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 53.24 | ★ 130.28 |
| 52 Week Low | $0.65 | $1.31 |
| 52 Week High | $2.09 | $7.39 |
| Indicator | LCTX | HYLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 87.16 |
| Support Level | $1.14 | $1.77 |
| Resistance Level | $1.80 | N/A |
| Average True Range (ATR) | 0.08 | 0.77 |
| MACD | 0.01 | 0.36 |
| Stochastic Oscillator | 55.56 | 92.09 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Hyliion Holdings Corp designs and develops power generators for stationary and mobile applications and provides R&D service. It provides solutions that enable clean, flexible, and affordable electricity production. The company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies. Its products and services include: KARNO Power Modules which is a modular, fully enclosed, fuel-agnostic and fully integrated power generating solution.